局部晚期或转移性肝细胞胆管癌的管理
Management of Locally Advanced or Metastatic Combined Hepatocellular Cholangiocarcinoma.
作者信息
Zhao Jemmy, Stephan-Falkenau Susann, Schuler Markus, Arndt Börge
机构信息
National Center of Tumor Diseases, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Institute of Pathology, Medizinisches Versorgungszentrum am Helios Klinikum Emil von Behring, Walterhöferstr. 11, 14165 Berlin, Germany.
出版信息
Cancers (Basel). 2023 Feb 3;15(3):988. doi: 10.3390/cancers15030988.
Combined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare primary liver malignancy that comprises features of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Due to the rarity of this tumor, the treatment of choice has not yet been defined. For resectable disease, liver resection is the mainstay treatment. However, most patients relapse or display advanced disease and were not surgical candidates. Although the majority of patients are either primarily or secondarily treated in palliative intent, no guideline recommendations or prospective trial reports exist to allow reliable evaluation of debated treatment options. We review different locoregional or medical treatment options for advanced combined hepatocellular cholangiocarcinoma (cHCC-CC) in the neoadjuvant, adjuvant, or palliative setting and discuss the possibility of predictive biomarker-guided therapeutic options.
肝内胆管癌合并肝细胞癌（cHCC-CC）是一种罕见的原发性肝脏恶性肿瘤，兼具肝细胞癌（HCC）和胆管癌（CC）的特征。由于这种肿瘤较为罕见，尚未确定其首选治疗方法。对于可切除的疾病，肝切除术是主要治疗手段。然而，大多数患者会复发或出现晚期疾病，并非手术候选者。尽管大多数患者接受的是姑息性的一线或二线治疗，但目前尚无指南推荐或前瞻性试验报告，无法对有争议的治疗方案进行可靠评估。我们回顾了在新辅助、辅助或姑息治疗背景下针对晚期肝内胆管癌合并肝细胞癌（cHCC-CC）的不同局部区域或药物治疗方案，并讨论了预测性生物标志物指导治疗方案的可能性。
Zotero 插件